Shimoli Shah is a Cardiology physician affiliated with Boehringer Ingelheim. OpenAlex indexes 31 publications with 850 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
13400 E Shea Blvd
Scottsdale, AZ 852595452
Telephone
480-301-8000Provider last certified this registry record 9 Feb 2023.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma Global DevelopmentProgram year20231 payment
- ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)Program year20221 payment
- ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
84.4%Statin27.5%Atorvastatin Calcium59%Rosuvastatin Calcium41%Part D≥61 patientsBeta blocker21.1%Metoprolol Succinate64%Carvedilol26%Metoprolol Tartrate10%Part D<11 patients+ 8 more classes in this area
Blood & clotting
14.1%Factor Xa inhibitor9.9%Eliquis86%Xarelto14%Part D<11 patientsVitamin K antagonist2.3%Warfarin Sodium100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
1.5%SGLT2 inhibitor1.5%Jardiance100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension Status
Kidney International Reports
2026 - Cumulative Effects of Vicadrostat and Empagliflozin on Albuminuria in CKD
American Journal of Kidney Diseases
2026 - Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses
Diabetes Obesity and Metabolism
2026
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”